Additionally, vorinostat has been shown to synergize with the proteasome inhibitors bortezomib in multiple myeloma and carfilzomib in DLBCL [5], [12], with the BH3 mimetic ABT-737 in breast cancer and in certain transgenic murine lymphomas [7], [13], and with the PKCβ inhibitor enzastaurin in DLBCL and T-cell lymphoma [9]. This evidence concerns the gene PRKCB and diffuse large B-cell lymphoma.